文献速递前列腺癌

分子PET/CT在前列腺癌根治术后生化复发患者挽救性放疗前的应用与影响:范围综述

Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.
PubMed 文献 · Eur Urol Oncol · 2021-02-24

本范围综述纳入45项研究,评估18F-fluciclovine、68Ga-PSMA-11和18F-DCFPyL PET/CT在根治性前列腺切除术后生化复发、挽救性放疗前的检出率、检出模式、管理改变及结局影响。多数研究显示检出率高且与PSA水平相关,PSMA配体在低PSA时敏感性可能优于fluciclovine;近50%患者管理改变,基于分子PET的放疗计划生化反应统计学上优于常规影像计划,且未增加泌尿生殖或胃肠道毒性。

要点

  • 分子PET/CT在根治术后生化复发、挽救性放疗前检出率高,且检出率与PSA水平相关。
  • PSMA配体在低PSA值时敏感性可能优于fluciclovine,但随机数据有限。
  • 分子PET/CT可改变近50%患者的管理,基于其的挽救性放疗生化反应更优且不增加毒性。

核心结论

  • 分子PET/CT在根治术后、挽救性放疗前常检出共识术后放疗野未覆盖的病灶,从而触发管理改变。
  • 基于分子PET的挽救性放疗生化反应统计学上优于常规影像计划,且未增加泌尿生殖或胃肠道毒性。
  • 病灶是否高摄取是强预后因素,正在进行中的试验将评估PSMA PET指导挽救性放疗的长期获益。

研究设计与样本

  • 纳入评估18F-fluciclovine、68Ga-PSMA-11和18F-DCFPyL PET在根治术后、挽救性放疗前检测复发疾病的已发表报告和摘要。
  • 共纳入45项研究进行定性综合。

主要发现

  • 多数研究检出率高,且前列腺特异性抗原(PSA)水平与阳性影像发现常存在明确关系。
  • 在低PSA值时,PSMA配体相比fluciclovine似乎敏感性增加,但随机数据有限。
  • 多数研究显示仅三分之一至二分之一的可检出病灶患者病灶仅位于前列腺窝。
  • 近50%接受分子影像的患者发生管理改变。
  • 基于分子PET的挽救性放疗生化反应范围为45%至94%,且未似乎以增加泌尿生殖或胃肠道毒性为代价。

关键数值与推荐

  • 共纳入45项研究进行定性综合。
  • 近50%接受分子影像的患者发生管理改变。
  • 基于分子PET的挽救性放疗生化反应范围为45%至94%。
  • 仅三分之一至二分之一的可检出病灶患者病灶仅位于前列腺窝。

临床怎么用

  • 根治术后生化复发、拟行挽救性放疗的患者可考虑分子PET/CT以更精准定位复发灶并指导放疗靶区。
  • 分子PET/CT检出的病灶常位于共识术后放疗野之外,可能改变放疗计划。
  • 基于分子PET的挽救性放疗可能提高生化反应且不增加毒性,但长期结局待试验确认。

局限性

  • 随机数据有限。
  • 证据为定性综合,未进行定量合并。
  • 正在进行中的试验将评估PSMA PET指导挽救性放疗对长期结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The use, common findings, and impact of modern molecular positron emission tomography (PET)/computed tomography (CT) imaging prior to salvage radiation therapy (RT) in men with biochemical recurrence after radical prostatectomy (RP) have not been evaluated comprehensively. OBJECTIVE: We performed a scoping systematic review of the literature assessing detection rates, detection patterns, changes in management, as well as changes in patient outcome resulting from molecular PET/CT imaging using three molecular tracers: 18F-fluciclovine, 8Ga prostate-specific membrane antigen (PSMA)-11, and 18F-DCFPyL. EVIDENCE ACQUISITION: A computerized bibliographic search of the Medline/PubMed database was carried out from inception to October 1, 2020. We included published reports and abstracts evaluating the utility of 1Fluciclovine, 68Ga-PSMA-11, and 18F-DCFPyL PET in the detection of recurrent disease in the post-RP, pre-salvage RT setting. Outcomes of interest were extracted and tabulated, and existing evidence was synthesized qualitatively. EVIDENCE SYNTHESIS: A total of 45 studies were included in our qualitative synthesis. Detection rates were high across most studies, and there was often a clear relationship between prostate-specific antigen (PSA) level and positive imaging findings. Though limited randomized data are available, there appears to be increased sensitivity with the use of PSMA ligands compared with fluciclovine at low PSA values. Most studies have shown that only one-third to one-half of patients with detected lesions have lesions in the prostatic fossa alone. Management changes occur in nearly 50% of patients undergoing molecular imaging, and biochemical response in patients who undergo molecular PET-based RT planning appears to be statistically superior to the response in patients who undergo conventional imaging -based RT planning alone. High biochemical responses from molecular PET-based salvage RT, ranging from 45% to 94%, did not appear to come at the expense of increased genitourinary or gastrointestinal toxicity. The presence or absence of avid lesions appears to be a strong prognostic factor. CONCLUSIONS: Molecular PET/CT imaging in the post-RP, pre-salvage RT setting often triggers management changes that result from detecting lesions in locations not typically included in consensus-driven postoperative RT fields. Ongoing trials will assess the benefit of PSMA PET in guiding salvage RT following RP and determine its impact on long-term outcomes. PATIENT SUMMARY: We reviewed and reported detection rates, detection patterns, and changes in management resulting from molecular positron emission tomography/computed tomography imaging in men with biochemically recurrent prostate cancer following radical prostatectomy. Prior to the receipt of salvage radiation therapy, molecular tracers targeting prostate-specific membrane antigen appear to be especially sensitive at identifying the place where prostate cancer has come back after surgery, which can help radiation oncologists better target the recurrent disease and potentially improve the rates of cure from prostate cancer in this setting. Future studies will determine whether these imaging tools will change cure rates and side effects, but early results are promising.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Valle L, Shabsovich D, de Meerleer G, et al. Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. Eur Urol Oncol. 2021. PMID: 33637464. doi:10.1016/j.euo.2021.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。